Top Pharmaceutical Companies in Los Angeles, CA (90)
GoodRx is America’s healthcare marketplace. Each month, millions of people visit goodrx.com to find reliable health information and discounts for their healthcare — and we’ve helped people save $35 billion since 2011. We provide prescription discounts that are accepted at more than 70,000 pharmacies in the U.S., as well as telehealth services including doctor visits and lab tests. Our goal is...
GoodRx's Top Stability & Growth Strengths
Product Line Growth: Feedback suggests newer offerings like Pharma Direct and subscriptions are expanding rapidly, indicating momentum beyond the legacy prescription-discount model.
Strategic Partnerships: Feedback suggests deepening relationships with pharmaceutical manufacturers are driving strong growth in Pharma Direct and expanding medication-access programs.
Healthy Cash Flow: Feedback suggests operating cash flow was strong in recent periods, even as total revenue was near flat and segment performance was mixed.
Best Formulations is a contract manufacturer specializing in the development and production of nutraceuticals, dietary supplements, and personal care products. Founded in 1984, the company provides manufacturing services for vitamins, minerals, and plant-based nutritional supplements. Following its acquisition by Sirio Pharma, it serves as a key manufacturing hub for global health and wellness brands, with operations spanning nutraceuticals and beauty...
IPS-Integrated Project Services, LLC, a Berkshire Hathaway company, is a global leader in developing innovative solutions for the consulting, architecture, engineering, project controls, procurement, construction management, and CQV of technically complex facilities worldwide. With technical expertise spanning R&D to pilot-scale to large-scale production, our team specializes in the technology, trends, and regulatory environment to successfully deliver capital projects and improve...
BENEV Company Inc. is an FDA-registered pharmaceutical, cosmeceutical, and medical device company founded in 2000 and based in Mission Viejo, California. It serves the global medical aesthetics market with science-backed, results-driven products, including exosome-based regenerative biologics, growth factor skincare, injectable medical devices such as PDO threads, and RF microneedling devices like Sylfirm X. Its mission is to inspire a more...
Emmaus Life Sciences, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of innovative treatments and therapies primarily for rare and orphan diseases.
Mixlab is the first modern, tech-enabled pet pharmacy that focuses on creating custom medications and delightful experiences for pets, their parents and veterinarians. By putting service at the heart of everything we do, our talented team is able to provide the best personalized care for our patients, as well as those who care for them.
Mixlab's Top Stability & Growth Strengths
Market Expansion: The company expanded from a few labs to a multi‑site footprint across NY, CA, FL, TX, and WI with shipping to all 50 states and same‑/next‑day options in select markets. Acquisitions in 2024–2025 (e.g., NexGen, The Pet Apothecary, SBH Medical’s veterinary business) broadened geographic coverage and capacity.
Investor Backing & Capital Strength: Recent capital raises, including a $10M round in 2023, funded nationwide scaling and platform development. Investor support is tied to new facilities and acquisitions that extend operational reach.
Innovation-Driven Growth: Technology integrations (e.g., Vetcove, Vetsource, Instinct EMR), a new client portal, and launch of an AI health partner (Maisy) underpin a tech‑first growth strategy. The model emphasizes a modern, veterinary‑friendly digital workflow and fast fulfillment.
Gemelli is a biotechnology company that specializes in the microbiome, and IBS diagnostics.
CG Oncology, Inc. (Nasdaq: CGON), is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. We see a world where urologic cancer patients can benefit from our innovative oncolytic immunotherapies to live with dignity and have an enhanced quality of life. Our lead candidate, cretostimogene grenadenorepvec, is an intravesically...
Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology for our purpose “to contribute to the enrichment of quality of life around the world.” In addition to our current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as...
Daiichi Sankyo's Top Stability & Growth Strengths
Strong Revenue Growth: Recent results indicate sustained year-over-year revenue increases driven primarily by the oncology franchise, notably ENHERTU and DATROWAY. Management maintains forward revenue growth guidance while highlighting continued indication and geographic expansion for these assets.
Strategic Partnerships: Large, multi‑asset collaborations with AstraZeneca and Merck validate the DXd platform and provide capital, development support, and commercial reach. These alliances underpin scale‑up and reinforce the medium‑term growth outlook in oncology.
Strong Market Position & Advantage: The company is recognized as a leader in oncology antibody‑drug conjugates, with ENHERTU establishing leading shares in key indications and additional approvals broadening use. Category leadership is further supported by expanding first‑line and tumor‑agnostic indications.
ICU Medical connects patients and caregivers through safe, life-saving, life-enhancing IV therapy systems, software, solutions, and consumables.
ACELYRIN, INC. is a biopharma company focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of promising drug candidates and leveraging its expertise to rapidly advance these medicines to patients. ACELYRIN is embedding a corporate culture of Courageous Caring™—placing patients first and embracing the concept that all of us are better than any...
Arrowhead Pharmaceuticals is a clinical stage, Nasdaq listed (ticker ARWR) company developing medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, our therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism...
Xencor is a clinical-stage biopharmaceutical company that discovers and develops engineered antibody therapeutics for patients with cancer and autoimmune diseases with unmet medical needs. Its XmAb protein-engineering platforms modify antibody Fc domains to improve biological function or create new therapeutic mechanisms, enabling purpose-built drug candidates. The company advances a broad portfolio through clinical development and also partners with biopharmaceutical companies...
Insulet Corporation, headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod® Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the...
Insulet's Top Stability & Growth Strengths
Strong Revenue Growth: Company reported accelerating revenue growth across 2024–2025 and guided continued double‑digit expansion for 2026. Quarterly updates highlighted broad‑based momentum in both U.S. and international markets.
Strong Market Position & Advantage: Omnipod leads the tubeless/patch‑pump segment and ranked No. 1 in new customer starts in the U.S. and Europe in 2024–2025, reinforcing competitive momentum. First‑to‑market AID clearance for adults with type 2 diabetes and broad CGM integrations bolster positioning.
Market Expansion: International rollouts and expansion into type 2 diabetes materially increased the addressable market and active user base. Added manufacturing capacity in Malaysia supports global demand and cost scaling.
NKGen Biotech is a clinical-stage biotechnology company developing and commercializing natural killer (NK) cell therapies using its proprietary SNK platform. Its autologous, allogeneic, and CAR-NK candidates are intended to treat neurodegenerative diseases, including Alzheimer’s and Parkinson’s, as well as cancers. The company’s platform uses activated NK cells, which it aims to bring to patients through clinical development and eventual commercialization.
A closed-door pharmacy working to disrupt, shake up, and give the chills to industry giants. We understand that truly changing the way patients access affordable prescriptions must first start with the team behind the counter (so to speak)! The Honeybee family works together to support each other and, in turn, our patients every day to improve pharmacy standards both within...
Authentica Media is a creative, full-service video storytelling agency specializing in the healthcare sector, specifically for MedTech and Pharma marketers. The agency collaborates with leading healthcare brands to create clinically accurate, human-centric video content that strengthens connections between brands, clinicians, and patients. Their mission is to make complex medical stories clear and accessible, ultimately helping patients find the medical innovations...
MDxHealth is a commercial-stage precision diagnostics company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer and other urologic diseases.
Edwards Lifesciences (NYSE: EW), is the global leader in patient-focused medical innovations for structural heart disease, as well as critical care and surgical monitoring. We thrive on discovery and expanding the boundaries of medical technology, serving patients in 100+ countries, with the help of our employees in areas including Clinical Affairs, Quality Engineering, Research & Development, Regulatory Affairs, Sales &...
Edwards Lifesciences's Top Stability & Growth Strengths
Strong Market Position & Advantage: Edwards is broadly characterized as the TAVR category leader anchored by the SAPIEN portfolio, and its first-to-approval EVOQUE tricuspid replacement reinforces leadership across structural heart. Industry trackers and company updates point to durable share and breadth across aortic, mitral, and tricuspid therapies.
Strong Revenue Growth: Recent results show double-digit top-line expansion and successive raises to the 2026 sales outlook, driven by steady TAVR demand and rapid TMTT growth. Management commentary emphasizes continued momentum with a consistent long-term growth ambition.
Innovation-Driven Growth: First-to-approval EVOQUE in tricuspid replacement, rapid uptake of PASCAL in mitral repair, and extensive long-term SAPIEN evidence position the portfolio for further adoption. Regulatory and policy catalysts, including a pending CMS TAVR coverage reconsideration and accumulating durability data, may expand access.
Clínica Monseñor Oscar A. Romero is a 501(c)(3) nonprofit Federally Qualified Health Center (FQHC) dedicated to providing quality, affordable, and culturally sensitive healthcare to underserved communities in greater Los Angeles. The clinic offers medical, dental, vision, pharmacy, and behavioral health services regardless of a patient's ability to pay, while honoring the legacy and teachings of Monseñor Oscar A. Romero.
